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haBACKGROUND Evidence suggests that interleukin (IL)-1b is important in the pathogenesis of atherosclerosis and its
complications and that inhibiting IL-1b may favorably affect vascular disease progression.
OBJECTIVES The goal of this study was to evaluate the effects of IL-1b inhibition with canakinumab versus placebo on
arterial structure and function, determined by magnetic resonance imaging.
METHODS Patients (N ¼ 189) with atherosclerotic disease and either type 2 diabetes mellitus or impaired glucose
tolerance were randomized to receive placebo (n ¼ 94) or canakinumab 150 mg monthly (n ¼ 95) for 12 months. They
underwent magnetic resonance imaging of the carotid arteries and aorta.
RESULTS There were no statistically signiﬁcant differences between canakinumab compared with placebo in the
primary efﬁcacy and safety endpoints. There was no statistically signiﬁcant change in mean carotid wall area and no
effect on aortic distensibility, measured at 3 separate anatomic sites. The change in mean carotid artery wall area was
–3.37 mm2 after 12 months with canakinumab versus placebo. High-sensitivity C-reactive protein was signiﬁcantly
reduced by canakinumab compared with placebo at 3 months (geometric mean ratio [GMR]: 0.568; 95% conﬁdence
interval [CI]: 0.436 to 0.740; p < 0.0001) and 12 months (GMR: 0.56; 95% CI: 0.414 to 0.758; p ¼ 0.0002). Lipo-
protein(a) levels were reduced by canakinumab compared with placebo (–4.30 mg/dl [range: –8.5 to –0.55 mg/dl];
p ¼ 0.025] at 12 months), but triglyceride levels increased (GMR: 1.20; 95% CI: 1.046 to 1.380; p ¼ 0.01). In these
patients with type 2 diabetes mellitus or impaired glucose tolerance, canakinumab had no effect compared with placebo
on any of the measures assessed by using a standard oral glucose tolerance test.
CONCLUSIONS There were no statistically signiﬁcant effects of canakinumab on measures of vascular structure or
function. Canakinumab reduced markers of inﬂammation (high-sensitivity C-reactive protein and interleukin-6), and
there were modest increases in levels of total cholesterol and triglycerides. (Safety & Effectiveness on Vascular
Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients; NCT00995930) (J Am Coll
Cardiol 2016;68:1769–80) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology
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1770A therosclerosis is well-established asa disease with an important inﬂam-matory component (1–3). Systemic
markers of inﬂammation such as C-reactive
protein and serum amyloid A are strongly
related to cardiovascular prognosis in vari-
ous populations and clinical settings (4,5).
Furthermore, therapeutic interventions that
reduce cardiovascular risk have also been
associated with a reduction in systemic in-
ﬂammatory markers (6,7). However, whether
speciﬁcally targeting inﬂammation reduces
cardiovascular risk remains unknown.
Interleukins are important mediators of
inﬂammation, both locally and systemically.
Macrophages are key cellular components of
atherosclerotic plaque and produce inter-
leukin (IL)-1b (8), which is also promoted by
cellular cholesterol activation of inﬂamma-
somes (9). IL-1b and interleukin-1a exertproinﬂammatory effects that are inhibited by the
endogenous antagonist interleukin-1 receptor antag-
onist (IL-1RA). Atherosclerosis-prone mice that are
deﬁcient in IL-1b develop smaller lesions (10),
and administration of IL-1RA reduces early athero-
genesis in mice (11). IL-1RA–deﬁcient mice have
shown increased atherosclerosis (12) and vascular
inﬂammation, associated with destruction of elastic
tissues (13).SEE PAGE 1781Therefore, given the key role for IL-1b as a medi-
ator of innate immunity and the effects of inter-
leukin inhibition in experimental atherosclerosis,
interventions to reduce inﬂammation through IL-1b
have been proposed to treat atherosclerosis. Although
evidence of beneﬁt to vascular disease in humans
remain sparse, administration of the IL-1RA anakinra
to patients with rheumatoid arthritis improved
several measures of vascular function, including
aortic distensibility, ﬂow-mediated vasodilation, and
coronary ﬂow reserve (14).
In addition to its key role in vascular disease, IL-1b
has been implicated in the pathogenesis of type 2 dia-
betes mellitus (T2DM). IL-1RA expression is reducedShire; during the study; and was an employee of Novartis. Dr.
hury was a Wellcome Trust Senior Research Fellow in Clinical Sc
al and personalized medicine and the University of Montreal endo
rted by the National Institute for Health Research Oxford Biomed
Ms. Birks). All other authors have reported that they have no re
un Yuan, PhD, served as Guest Editor for this paper.
received January 27, 2016; revised manuscript received June 30in pancreatic islets of patients with T2DM, and high
glucose concentrations induce the production of IL-1b
in human pancreatic beta cells, leading to impaired
insulin secretion, decreased cell proliferation, and
apoptosis (15). Blockade of the interleukin-1 receptor
with anakinra improved glycemia and beta-cell
secretory function and reduced markers of systemic
inﬂammation in patients with T2DM (16). Patients with
T2DM are at high risk for cardiovascular disease (17)
and have evidence of both increased plaque inﬂam-
mation (18) and reduced arterial distensibility (19).
This group might, therefore, derive “metabolic” and
“vascular” beneﬁts from targeting IL-1b, including
reduced risk of atherothrombotic complications.
A human monoclonal anti-human IL-1b antibody of
the immunoglobulin G1/k isotype canakinumab
functionally neutralizes IL-1b through steric hin-
drance of its receptor interaction. It is effective
in reducing systemic markers of inﬂammation,
including C-reactive protein and IL-6 (20). Its effects
on cardiovascular outcomes are under investigation
in the CANTOS (Canakinumab Anti-inﬂammatory
Thrombosis Outcomes Study) trial (21).
Vascular magnetic resonance imaging (MRI) has
emerged as a precise, highly reproducible, and ver-
satile tool to assess both vascular structure and
function at multiple arterial loci (22–25). Accordingly,
we designed a randomized, placebo-controlled Phase
II clinical trial to test the effects of IL-1b inhibition,
using canakinumab, on: 1) MRI-derived measures of
vascular structure and function; 2) measures of dia-
betes control; and 3) indicators of systemic inﬂam-
mation in patients with atherosclerotic vascular
disease and impaired glucose tolerance (IGT) or
T2DM.
METHODS
Novartis Pharmaceuticals (Cambridge, Massachusetts)
initiated this Phase II, double-blind, randomized,
placebo-controlled trial, with the ﬁnal study protocol
designed in collaboration with the investigators
(R.P.C., J.-C.T., and Z.A.F.), based on their previously
published methods (19,23,24). The study was under-
taken at 9 centers in Canada, the United Kingdom,Fayad has received research support from Novartis.
ience. Dr. Tardif holds the Canada Research Chair in
wed research chair in atherosclerosis. This work was
ical Research Centre (Drs. Choudhury, Biasiolli, and
lationships relevant to the contents of this paper to
, 2016, accepted July 6, 2016.
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1771the United States, Germany, and Israel, in compliance
with the principles of the Declaration of Helsinki
and according to Good Clinical Practice guidelines.
The protocol was reviewed and approved by the
institutional review board, or equivalent, for each
center. All participants provided written informed
consent before undertaking any study procedures.
PATIENTS. Patients (ages 18 to 74 years) were eligible
for inclusion if they had clinically evident athero-
sclerotic vascular disease: previous myocardial
infarction; history of angina; carotid stenosis (>30%);
peripheral vascular disease (ankle–brachial index
<0.9); endarterectomy >3 months previously; or
transient ischemic attack or stroke. In addition, pa-
tients must also have had either T2DM (for #14 years
and glycosylated hemoglobin [HbA1c] levels between
6% and 10%) or IGT (deﬁned as a peak 2-h glucose
reading $140 mg/dl but <200 mg/dl after an oral
glucose tolerance test during screening). Patients
were to have been on stable statin therapy for a
period of $6 weeks before screening (or have
physician-documented statin intolerance).
After consent, eligible patients were randomized
(1:1) to receive canakinumab 150 mg or placebo, sub-
cutaneously, monthly for 12 months. Exclusion
criteria included: pregnancy; systemic steroid use;
baseline high-sensitivity C-reactive protein (hs-CRP)
levels >30 mg/l; history of signiﬁcant multiple drug
allergies; history or evidence of chronic infection,
including tuberculosis and liver disease; or a standard
contraindication to MRI. Randomization occurred
between December 2009 and November 2012. Patient
groups were assigned centrally according to a vali-
dated computer-generated randomization code,
stratiﬁed according to glycemic status (T2DM or IGT).
IMAGING PROCEDURES. An integrated vascular MRI
was performed at baseline and after 3 and 12 months of
treatment. If the imaging data did not meet an evalu-
able standard at any time point, the patient was
rescanned. Randomization required an evaluable
baseline scan. The imaging procedure comprised
measures of aortic wall area and distensibility, as well
as carotid wall area bilaterally. The imaging protocol
was adapted from Lee et al. (19), and staff at each im-
aging site underwent individualized training to ensure
consistency of method and data acquisition. All trial
sites used a 3.0-T whole-body MRI scanner, including
Trio, TIM Trio, or Verio (Siemens Medical Solutions
USA, Inc., Malvern, Pennsylvania) or Achieva (Philips,
Amsterdam, the Netherlands) platforms. For carotid
imaging, a bilateral 4-channel carotid array (Machnet
B.V., Roden, theNetherlands)was used on the Siemens
scanners and an equivalent multi-channel (4 to 8)phased array carotid coil (Shanghai Medical, Shanghai,
China) was used on the Philips scanners.
Detailed information regarding imaging protocols
and analysis is available in the Online Appendix.
The velocity at which the arterial pulse propagates
is termed pulsed wave velocity (PWV). A measure of
arterial stiffness, it is an independent predictor of
mortality in both T2DM and IGT (26). The Sphygmo-
cor platform (AtCor Medical Pty. Ltd., West Ryde,
Australia) was applied immediately before MRI
scanning to acquire the aortic central pulse pressure
from radial artery applanation tonometry and the
PWV from the carotid-femoral pulse waves.
SAFETY ASSESSMENTS. Monitoring of vital signs,
electrocardiogram, standard hematology, and bio-
chemistry (including measurement of lipoproteins,
liver function, and creatine kinase) were conducted
throughout the study. A data monitoring committee
oversaw subject safety on an ongoing basis. In addi-
tion, 3 adjudication committees made blinded as-
sessments of adverse events in relation to cardiac,
malignant, and infection-related events.
ENDPOINTS. The primary efﬁcacy objectives were the
effects of the drug on aortic distensibility and total
plaque burden in the aorta and carotid arteries; the
primary safety objective was the safety and tolera-
bility of canakinumab in this population. Secondary
objectives included the effects of canakinumab
on aortic PWV; hs-CRP; HbA1c; homeostasis model
assessment (HOMA)–insulin resistance; and peak
blood glucose level 2 h after an oral glucose challenge.
Exploratory analyses of peripheral biomarkers of
inﬂammation (including IL-6, serum amyloid A, and
plasma lipoproteins) were also performed.
STATISTICAL ANALYSES. Sample size was calculated
from the study of Lee et al. (19). To detect a 35%
change in aortic distensibility or an 11% change in
plaque burden at 12 months to achieve a power of 0.8
and nominal p < 0.05 (2-sided), 60 patients per group
were required. To ensure 120 datasets with 12-month
follow-up data, it was planned to randomize 190 pa-
tients. Given the exploratory nature of the study,
corrections were not made for the multiplicity of
statistical tests. As deﬁned by the protocol, patients
were included in the 3-month data analysis if they
had no missing doses at 3 months; for the 12-month
analysis, participants were required to have no
missing doses by 3 months and 1 or no missing doses
between 3 and 12 months.
To compare treatment with placebo, we conducted
an analysis of covariance on change from baseline,
including the glycemic status as a factor and the
baseline as a covariate at 3 and 12 months. All data
TABLE 1 Baseline Characteristics
Canakinumab
(n ¼ 95)
Placebo
(n ¼ 94)
Male 82 (86) 80 (85)
Age, yrs 61.7  7.8 61.9  6.9
Diabetes 81 (85) 81 (86)
Hypertension 81 (85) 83 (88)
Systolic blood pressure, mm Hg 128.7  10.3 128.4  10.0
Diastolic blood pressure, mm Hg 76.6  8.1 76.9  9.1
Current smoker 7 (7) 7 (7)
Peripheral vascular disease 8 (8) 8 (8)
Previous stroke 21 (22) 22 (23)
CAD 79 (83) 90 (96)
Medications
ACE inhibitor 66 (69) 72 (77)
Beta-blocker 62 (65) 75 (80)
Statin 92 (97) 94 (100)
Insulin 29 (31) 26 (28)
Antiplatelet agent* 90 (95) 89 (95)
BMI, kg/m2 30.3  4.1 30.3  4.0
hs-CRP, mg/l 1.77 (0.84–3.74) 1.85 (0.83–3.88)
IL-6, ng/l 2.20 (1.61–3.63) 2.24 (1.60–3.30)
Serum amyloid A, mg/l 3.8 (1.9–6.3) 3.0 (1.9–6.8)
Adiponectin, ng/ml 3,685 (2,860–5,740) 3,880 (2,620–4,950)
Lp(a), mg/dl 18.8 (4.1–37.7) 15.1 (2.0–40.7)
LDL cholesterol, mg/dl 90.5  33.3 88.6  36.3
HDL cholesterol, mg/dl 42.5  10.4 41.8  10.4
Triglycerides, mg/dl 147  106 138  72
Duration of diabetes, yrs
#1 5 7
>1 and <5 22 16
$5 54 58
Fasting blood glucose, mg/dl 144  48 146  48
Insulin, pmol/l 77 (53–133) 72 (51–120)
HOMA-IR 3.7 (2.4–6.6) 3.6 (2.4–6.1)
HbA1c, % 7.03  1.02 6.85  0.93
HbA1c
#7% 50 52
>7% and <7.5% 14 20
$7.5% 29 21
Values are n (%), mean  SD, or median (interquartile range). *Aspirin, clopidogrel,
prasugrel, or ticagrelor. For HbA1c, there are 2 missing values for canakinumab and 1 for the
control group.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CAD ¼ coronary artery disease;
HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeostatic
model assessment–insulin resistance; hs-CRP ¼ high-sensitivity C-reactive protein; IL ¼ inter-
leukin; LDL ¼ low-density lipoprotein; Lp(a) ¼ lipoprotein(a).
TABLE 2 Subject Disposition
Placebo
(n ¼ 94)
Canakinumab
(n ¼ 95)
Total
(N ¼ 189)
Patients
Completed 73 (77.7) 67 (70.5) 140 (74.1)
Discontinued* 21 (22.3) 28 (29.5) 49 (25.9)
Main cause of discontinuation
Adverse event(s)* 11 (11.7) 14 (14.7) 25 (13.2)
Consent withdrawal 3 (3.2) 4 (4.2) 7 (3.7)
Lost to follow-up 1 (1.1) 2 (2.1) 3 (3.2)
Administrative 4 (4.3) 2 (2.1) 6 (3.2)
Death 0 (0) 1 (1.1) 1 (0.5)
Protocol deviation 2 (2.1) 5 (5.3) 7 (3.7)
Values are n (%). *There was no signiﬁcant difference between canakinumab
compared with placebo for the overall rate of discontinuation from the study (risk
ratio: 1.32; 95% conﬁdence interval: 0.81 to 2.15; p ¼ 0.26) or the rate of
discontinuation due to adverse events (risk ratio: 1.26; 95% conﬁdence interval:
0.60 to 2.63; p ¼ 0.54).
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1772were checked for normality and log-transformed, if
appropriate. When a log transformation of the change
from baseline was not possible because of negative
values, an analysis of covariance was conducted on
the log-transformed 3- and 12-month data, including
glycemic index status as a factor and the log-
transformed baseline as a covariate. We considered
a p value <0.05 as signiﬁcant. Results are reported
as means with 95% conﬁdence limits. Two interim
analyses were pre-speciﬁed, when n ¼ 60 and allpatients had completed 3 months of treatment,
respectively, with the intention of halting the study if
adverse measures were identiﬁed or for futility but
not for interim positive efﬁcacy. The interim analyses
were performed by independent personnel not
directly associated with the study’s conduct.
The study sponsor and funder (Novartis) partici-
pated in discussions about the design and conduct of
this study; they also provided the drugs used in
the trial and logistical support for its execution. The
trial design, endpoints, and statistical analyses were
largely derived from the academic investigators’
previously published studies (19,23,24). Following
the ﬁnal database lock, all patient data were analyzed
independently by the Centre for Statistics in Medi-
cine, Oxford (J.B.). The manuscript was drafted by
the academic investigators (R.P.C., J.S.B., J.-C.T., and
Z.A.F.), in accordance with the written agreement
between Novartis and the academic institutions,
and reviewed and revised by the writing committee.
All authors had full access to all the data in the study
and assume responsibility for publication.
All statistical analyses were performed by using
Stata 14 (StataCorp LP, College Station, Texas).
RESULTS
Of 450 patients screened, 189 were randomized to
receive either placebo (n ¼ 94) or canakinumab 150
mg (n ¼ 95). The proportions of patients with dia-
betes, duration of diabetes, and glycemic control
(estimated from HbA1c) were similar in the groups,
and there was a high prevalence for each of hyper-
tension, dyslipidemia, and background coronary
artery disease (Table 1); the latter was slightly higher
proportionately in the placebo group. There was no
TABLE 3 Change From Baseline in MRI Measures
3 Months 12 Months
No. of Patients:
LSM (95% CI), p Value
No. of Patients:
LSM (95% CI), p Value
Mean (R & L) carotid wall area, mm2
Canakinumab n ¼ 63; 0.97 (–1.55 to 3.48) n ¼ 48; 0.59 (–2.40 to 3.59)
Placebo n ¼ 67; 2.13 (–0.37 to 4.64) n ¼ 55; 3.96 (0.94 to 6.98)
Canakinumab vs.
placebo
–1.17 (–4.17 to 1.84), p ¼ 0.44 –3.37 (–6.90 to 0.16), p ¼ 0.06
Proximal ascending aorta wall area, mm2
Canakinumab n ¼ 64; 2.12 (–10.61 to 14.85) n ¼ 50; 11.20 (–9.77 to 32.16)
Placebo n ¼ 69; 16.12 (2.90 to 29.34) n ¼ 59; 30.26 (9.57 to 50.96)
Canakinumab vs.
placebo
–14.00 (–29.82 to 1.82),
p ¼ 0.08
–19.07 (–44.00 to 5.87), p ¼ 0.13
Proximal descending aorta wall area, mm2
Canakinumab n ¼ 75; 9.01 (–2.17 to 20.19) n ¼ 63; 20.92 (5.06 to 36.78)
Placebo n ¼ 80; 6.26 (–5.18 to 17.69) n ¼ 67; 25.28 (8.54 to 42.02)
Canakinumab vs.
placebo
2.75 (–10.57 to 16.08),
p ¼ 0.68
–4.36 (–23.63 to 14.92), p ¼ 0.66
Distal descending aorta wall area, mm2
Canakinumab n ¼ 67; 3.08 (–7.08 to 13.25) n ¼ 56; 14.65 (0.86 to 28.45)
Placebo n ¼ 73; –4.41 (–14.76 to 5.95) n ¼ 64; 21.02 (6.67 to 35.36)
Canakinumab vs.
placebo
7.49 (–4.74 to 19.72),
p ¼ 0.23
–6.36 (–23.49 to 10.77), p ¼ 0.46
Ascending aorta distensibility,  103 mm Hg–1
Canakinumab n ¼ 66; 0.00 (–0.26 to 0.27) n ¼ 51; –0.11 (–0.38 to 0.17)
Placebo n ¼ 61; –0.13 (–0.41 to 0.16) n ¼ 53; –0.13 (–0.43 to 0.17)
Canakinumab vs.
placebo
0.13 (–0.20 to 0.46),
p ¼ 0.44
0.03 (–0.32 to 0.370), p ¼ 0.87
Proximal descending aorta distensibility,  103 mm Hg–1
Canakinumab n ¼ 70; 0.08 (–0.23 to 0.39) n ¼ 56; –0.19 (–0.53 to 0.16)
Placebo n ¼ 71; 0.10 (–0.22 to 0.41) n ¼ 62; –0.25 (–0.60 to 0.11)
Canakinumab vs.
placebo
–0.02 (–0.39 to 0.35),
p ¼ 0.93
0.06 (–0.36 to 0.48), p ¼ 0.78
Distal descending aorta distensibility,  103 mm Hg–1
Canakinumab n ¼ 72; 0.04 (–0.32 to 0.40) n ¼ 54; –0.14 (–0.59 to 0.31)
Placebo n ¼ 74; 0.12 (–0.24 to 0.49) n ¼ 64; –0.20 (–0.66 to 0.25)
Canakinumab vs. placebo –0.09 (–0.51 to 0.34), p ¼ 0.69 0.06 (–0.48 to 0.61), p ¼ 0.82
Least squared means (LSM) of outcomes (95% conﬁdence intervals [CIs]) and number of patients in each group
reported from the analysis of covariance of the change from baseline at 3 and 12 months, adjusted for baseline of
outcome and including the 2-level factor type 2 diabetes mellitus or impaired glucose tolerance as a covariate.
Inclusion of patients is according to the protocol. Data from an end-of-study scan of 8 patients who left the trial
early were included if the time of the scan was within the allowed time limits for the 3-month scan (82 to 130
days).
L ¼ left; MRI ¼ magnetic resonance imaging; R ¼ right; other abbreviations as in Table 2.
J A C C V O L . 6 8 , N O . 1 6 , 2 0 1 6 Choudhury et al.
O C T O B E R 1 8 , 2 0 1 6 : 1 7 6 9 – 8 0 Effects of Canakinumab on Arterial Structure and Function
1773signiﬁcant difference between the canakinumab
group compared with the placebo group for the
overall rate of completion of the study, which was
70.5% with canakinumab versus 77.7% for placebo
(risk ratio: 1.32; 95% conﬁdence interval [CI]: 0.81 to
2.15; p ¼ 0.26) or the rate of discontinuation due to
adverse events (14.7% vs. 11.7%; risk ratio: 1.26; 95%
CI: 0.60 to 2.63; p ¼ 0.54) (Table 2). The most common
cause for discontinuation was for adverse events. A
full list of adverse events is provided in Online
Table 1. Seven patients withdrew consent, and 7 pa-
tients were excluded from analysis due to signiﬁcant
protocol deviation.
As a biomarker of atherosclerotic plaque burden,
vessel wall area was quantiﬁed in the aorta and ca-
rotid arteries (Table 3). There was no statistically
signiﬁcant difference in mean carotid wall area be-
tween these 2 groups at either time point. Baseline
mean carotid wall areas were 27.7  9.79 mm2 and
27.1  9.6 mm2 (p ¼ NS) for the canakinumab and
placebo groups, respectively. Change in mean carotid
artery wall area was –3.37 mm2 (p ¼ 0.06) after 12
months for canakinumab versus placebo. There was
an increase (12 months vs. baseline) in wall area for
each of the left and right carotid arteries (and mean of
the left and right) with placebo but, on average,
neither progression nor regression in the canakinu-
mab group (Figure 1A). Change from baseline at
12 months was compared for individual patients be-
tween the left and right carotid arteries for both
treatment groups. In each, there were strong correla-
tions between changes in the left and right carotid
arteries for canakinumab and placebo, respectively
(p < 0.0001 for both) (Figure 1B). The vessel lumen
area was not changed by canakinumab treatment.
There was no statistically signiﬁcant difference in wall
area between canakinumab treatment and placebo at
any of the 3 aortic sites at either 3 or 12 months.
Aortic distensibility was calculated from measure-
ments made at 3 sites in the aorta. There were no
statistically signiﬁcant differences between canaki-
numab treatment and placebo for change in aortic
distensibility, and no signiﬁcant changes occurred in
systolic or diastolic blood pressure at either 3 or
12 months of treatment versus baseline. There were
also no signiﬁcant differences in measures of PWV
between these 2 groups at either time point (Table 3).
Compared with placebo, canakinumab reduced hs-
CRP at 3 months (geometric mean ratio [GMR]: 0.568;
95% CI: 0.436 to 0.740; p < 0.0001) and 12 months
(GMR: 0.56; 95% CI: 0.414 to 0.758; p ¼ 0.0002)
(Figure 2). Similarly, IL-6 was reduced by canakinu-
mab at the 3-month time point (GMR: 0.580; 95% CI:
0.483 to 0.697; p < 0.0001). Neither serum amyloidA nor adiponectin changed signiﬁcantly in response
to canakinumab treatment compared with placebo
(Table 4).
In this study population of patients with T2DM or
IGT and near-universal statin use, canakinumab had
no effect on either plasma low-density lipoprotein or
high-density lipoprotein cholesterol levels compared
with placebo at either of the 3- or 12-month time
points. Levels of total plasma cholesterol were mildly
elevated from baseline in the canakinumab-treated
patients at 3 months compared with the placebo
group (GMR: 1.120; 95% CI: 1.050 to 1.195; p ¼ 0.0008)
but not at 12 months (GMR: 1.084; 95% CI: 0.991 to
1.185; p ¼ 0.08). The elevation in total cholesterol
FIGURE 1 Changes in Carotid Wall Area
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We evaluated 12-month change from baseline in wall area as an indicator of atherosclerosis
progression. (A) In both left and right carotid arteries, canakinumab retarded progression of
wall area compared with placebo. Consistent in magnitude and direction, the changes did
not reach statistical signiﬁcance in the mean carotid wall area (pre-stated endpoint) or in
either carotid artery analyzed separately. Bars ¼means with 95% conﬁdence intervals. (B)
Within the same patient, there was a striking concordance of change in wall area between
left- and right-sided arteries, which was maintained in both treatment groups (p < 0.0001
for each). Upper right quadrant ¼ patients with progression in both carotid arteries.
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rich lipoproteins, given the coinciding elevation in
triglyceride level that also accompanied canakinumab
treatment compared with placebo at 3 months (GMR:
1.21; 95% CI: 1.082 to 1.358; p ¼ 0.001) and 12 months
(GMR: 1.20; 95% CI: 1.046 to 1.380; p ¼ 0.01).
Lipoprotein(a) levels were reduced by canakinu-
mab compared with placebo. Changes from baseline
values were as follows: at 3 months, mean change was
–3.719 mg/dl (95% CI: –6.809 to –0.628; p ¼ 0.02); at
12 months, mean change was –4.300 mg/dl (95% CI:
–8.052 to –0.548; p ¼ 0.025).In this population of patients with T2DM (86%)
or IGT (14%) and with median baseline HbA1c
levels <7%, canakinumab also had no signiﬁcant
effect compared with placebo on fasting blood
glucose, HbA1c, HOMA–insulin resistance or HOMA-b,
or 2-h glucose, obtained as part of an oral glucose
tolerance test.
Major adverse cardiovascular events occurred in
9.0% of patients, with no signiﬁcant difference be-
tween the active treatment group (11%) compared
with the placebo group (7%) (risk ratio: 1.41; 95% CI:
0.56 to 3.56; p ¼ 0.46) (Table 5). A full list of adverse
events is given in Online Table 1.
DISCUSSION
Inﬂammation contributes to the pathogenesis of
vascular dysfunction and atherogenesis, as well as to
the complications of atherosclerosis (1). Data from
preclinical studies have suggested that inhibiting IL-1b
may directly affect atherosclerosis and vascular
inﬂammation (10).
In the present randomized clinical trial of IL-1b
inhibition in patients with T2DM or IGT, canakinumab
150 mg monthly reduced blood levels of IL-6 and
hs-CRP (Central Illustration). Similar reductions in
inﬂammatory indexes have been reported previously
in patients with T2DM (20). Signiﬁcantly, given the
target population, the present study showed that this
effect persists even with near-universal statin use.
Canakinumab had no effect on fasting glucose, HbA1c,
or measures of insulin sensitivity.
In common with earlier studies (19,23,24), athero-
sclerosis burden was quantiﬁed in the common
carotid arteries and the aorta. We found no statisti-
cally signiﬁcant effect of 12 months’ treatment with
canakinumab on magnetic resonance–derived mea-
sures of vascular structure or function. However, in
each of the common carotid arteries individually, and
in the combined vessel average, there was a sugges-
tion of possible retarded progression of atheroscle-
rotic burden.
Because atherosclerosis is a systemic disease, we
performed a further analysis, comparing changes in
the right and left carotid arteries within individual
patients. There were strong relationships between
changes in the left- versus right-sided vessels evident
in both the canakinumab and the placebo groups but
with a tendency toward progression bilaterally in the
placebo group. As detailed earlier, analyses of wall
area were conducted by operators who were blinded
to the timing and treatment allocation of the images.
Moreover, measurements were made separately on
individual slices, but the data presented are for
FIGURE 2 Changes in Lipids and C-Reactive Protein
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Absolute level or change from baseline at 3 and 12 months are shown for (A) C-reactive protein; (B) lipoprotein(a) (Lp[a]); (C) total cholesterol; (D)
high-density lipoprotein (HDL) cholesterol; and (E) triglycerides.
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stringency, these consistent correlations supported
the technical robustness of the measurements.
In common with previous studies, we chose
to quantify vessel wall area in the tubular carotid
arteries because they are less susceptible to error in
serial measurements due to “volume averaging”effects. Previously described techniques allow plaque
lipid quantiﬁcation with the use of T2 mapping,
but these were not current at the time of protocol
design (27). Lipid elements may be the most readily
mobilized components of atherosclerotic plaque,
although the mechanisms by which IL-1b in-
hibition might affect plaque lipid are not clear.
TABLE 4 Blood Measures for Lipids, Diabetes Control, and Markers of Inﬂammation
3 Months 12 Months
No. of Patients; LSM (95% CI), p Value
LDL cholesterol, mg/dl
Log-transformed results
Canakinumab n ¼ 64; 4.425 (4.343 to 4.508) n ¼ 55; 4.515 (4.414 to 4.616)
Placebo n ¼ 75; 4.361 (4.278 to 4.444) n ¼ 65; 4.460 (4.357 to 4.563)
Canakinumab vs. placebo 0.065 (–0.029 to 0.158), p ¼ 0.18 0.055 (–0.064 to 0.174), p ¼ 0.36
Back-transformed results
Canakinumab 83.52 (76.94 to 90.75) 91.38 (82.60 to 101.10)
Placebo 78.34 (72.10 to 85.12) 86.49 (78.03 to 95.88)
Canakinumab/placebo 1.067 (0.971 to 1.171) 1.057 (0.938 to 1.190)
Total cholesterol, mg/dl
Log-transformed results
Canakinumab n ¼ 49; 5.153 (5.098 to 5.208) n ¼ 40; 5.193 (5.119 to 5.267)
Placebo n ¼ 58; 5.040 (4.983 to 5.096) n ¼ 52; 5.113 (5.037 to 5.188)
Canakinumab vs. placebo 0.113 (0.048 to 0.178), p ¼ 0.0008 0.081 (–0.009 to 0.170), p ¼ 0.08
Back-transformed results
Canakinumab 173.0 (163.7 to 182.7) 180.0 (167.2 to 193.8)
Placebo 154.5 (145.9 to 163.4) 166.2 (154.0 to 179.1)
Canakinumab/placebo 1.120 (1.050 to 1.195) 1.084 (0.991 to 1.185)
Triglycerides, mg/dl
Log-transformed results
Canakinumab n ¼ 73; 4.938 (4.843 to 5.033) n ¼ 62; 4.979 (4.865 to 5.093)
Placebo n ¼ 79; 4.746 (4.646 to 4.845) n ¼ 70; 4.795 (4.676 to 4.915)
Canakinumab vs. placebo 0.192 (0.079 to 0.306), p ¼ 0.001 0.184 (0.045 to 0.322), p ¼ 0.01
Back-transformed results
Canakinumab 139.5 (126.8 to 153.4) 145.3 (129.7 to 162.9)
Placebo 115.1 (104.2 to 127.1) 120.9 (107.3 to 136.3)
Canakinumab/placebo 1.212 (1.082 to 1.358) 1.202 (1.046 to 1.380)
HDL cholesterol, mg/dl*
Canakinumab n ¼ 73; 1.779 (0.309 to 3.252) n ¼ 62; 0.731 (–1.017 to 2.479)
Placebo n ¼ 79; –0.282 (–1.817 to 1.257) n ¼ 70; –0.182 (–1.910 to 1.640)
Canakinumab vs. placebo 2.061 (0.302 to 3.821), p ¼ 0.02 0.913 (–1.214 to 3.039), p ¼ 0.40
Lp(a), mg/dl*
Canakinumab n ¼ 56; –3.325 (–5.835 to –0.816) n ¼ 47; –3.083 (–6.066 to –0.100)
Placebo n ¼ 59; 0.394 (–2.333 to 3.120) n ¼ 51; 1.217 (–2.059 to 4.493)
Canakinumab vs. placebo –3.719 (–6.809 to –0.628), p ¼ 0.02 –4.300 (–8.052 to –0.548), p ¼ 0.025
No. of Patients; Mean (95% CI on Log Scale)
HbA1c, %
Log-transformed results
Canakinumab n ¼ 73; 1.919 (1.900 to 1.942) n ¼ 60; 1.930 (1.897 to 1.963)
Placebo n ¼ 80; 1.918 (1.894 to 1.943) n ¼ 69; 1.922 (1.886 to 1.958)
Canakinumab vs. placebo 0.001 (–0.025 to 0.027), p ¼ 0.95 0.008 (–0.031 to 0.047), p ¼ 0.68
Back-transformed results
Canakinumab 6.814 (6.686 to 6.973) 6.890 (6.666 to 7.121)
Placebo 6.807 (6.646 to 6.980) 6.835 (6.593 to 7.085)
Canakinumab/placebo 1.001 (0.975 to 1.027) 1.008 (0.969 to 1.048)
Fasting blood glucose, mg/dl
Log-transformed results
Canakinumab n ¼ 71; 4.928 (4.868 to 4.989) n ¼ 58; 4.922 (4.845 to 4.999)
Placebo n ¼ 78; 4.849 (4.786 to 4.912) n ¼ 68; 4.853 (4.773 to 4.934)
Canakinumab vs. placebo 0.079 (0.013 to 0.145), p ¼ 0.02 0.068 (–0.017 to 0.154), p ¼ 0.12
Back-transformed results
Canakinumab 138 (130 to 147) 137 (127 to 148)
Placebo 128 (120 to 136) 128 (118 to 139)
Canakinumab/placebo 1.082 (1.013 to 1.156) 1.070 (0.983 to 1.166)
Continued on the next page
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TABLE 4 Continued
No. of Patients; Mean (95% CI on Log Scale)
HOMA-IR
Log-transformed results
Canakinumab n ¼ 67; 1.443 (1.282 to 1.603) n ¼ 56; 1.324 (1.133 to 1.514)
Placebo n ¼ 76; 1.358 (1.190 to 1.527) n ¼ 68; 1.278 (1.082 to 1.473)
Canakinumab vs. placebo 0.084 (–0.094 to 0.262), p ¼ 0.35 0.046 (–0.170 to 0.262), p ¼ 0.67
Back-transformed results
Canakinumab 4.233 (3.604 to 4.968) 3.758 (3.105 to 4.545)
Placebo 3.888 (3.287 to 4.604) 3.589 (2.951 to 4.362)
Canakinumab/placebo 1.088 (0.910 to 1.300) 1.047 (0.844 to 1.300)
HOMA-B
Log-transformed results
Canakinumab n ¼ 66; 4.066 (3.886 to 4.247) n ¼ 56; 3.969 (3.773 to 4.165)
Placebo n ¼ 76; 4.224 (4.033 to 4.415) n ¼ 68; 4.133 (3.929 to 4.337)
Canakinumab vs. placebo –0.158 (–0.361 to 0.046), p ¼ 0.13 –0.164 (–0.389 to 0.062), p ¼ 0.15
Back-transformed results
Canakinumab 58.32 (48.72 to 69.90) 52.93 (43.51 to 64.39)
Placebo 68.31 (56.43 to 82.68) 62.36 (50.86 to 76.48)
Canakinumab/placebo 0.854 (0.697 to 1.047) 0.849 (0.678 to 1.064)
C-reactive protein, mg/l
Log-transformed results
Canakinumab n ¼ 74; –0.278 (–0.500 to –0.056) n ¼ 61; –0.170 (–0.419 to 0.078)
Placebo n ¼ 79; 0.287 (0.051 to 0.523) n ¼ 69; 0.409 (0.145 to 0.673)
Canakinumab vs. placebo –0.565 (–0.829 to –0.301), p < 0.0001 –0.579 (–0.881 to –0.277), p ¼ 0.0002
Back-transformed results
Canakinumab 0.757 (0.607 to 0.946) 0.848 (0.658 to 1.081)
Placebo 1.332 (1.052 to 1.687) 1.505 (1.156 to 1.9690)
Canakinumab/placebo 0.568 (0.436 to 0.740) 0.561 (0.414 to 0.758)
IL-6, pg/ml
Log-transformed results
Canakinumab n ¼ 48; 0.367 (0.205 to 0.529) n ¼ 13; 0.744 (0.313 to 1.745)
Placebo n ¼ 48; 0.913 (0.742 to 1.081) n ¼ 14; 1.147 (0.729 to 1.565)
Canakinumab vs. placebo –0.544 (–0.728 to –0.361), p < 0.0001 –0.403 (–0.888 to 0.081), p ¼ 0.10
Back-transformed results
Canakinumab 1.443 (1.228 to 1.697) 2.104 (1.368 to 5.726)
Placebo 2.492 (2.100 to 2.948) 3.149 (2.073 to 4.783)
Canakinumab/placebo 0.580 (0.483 to 0.697) 0.668 (0.411 to 1.084)
Serum amyloid A, mg/l
Log-transformed results
Canakinumab n ¼ 67; 0.963 (0.760 to 1.166) n ¼ 56; 1.000 (0.795 to 1.205)
Placebo n ¼ 76; 1.129 (0.922 to 1.336) n ¼ 69; 1.243 (1.032 to 1.453)
Canakinumab vs. placebo –0.166 (–0.408 to 0.077), p ¼ 0.18 –0.243 (–0.493 to 0.008), p ¼ 0.06
Back-transformed results
Canakinumab 2.620 (2.138 to 3.209) 2.718 (2.214 to 3.337)
Placebo 3.093 (2.514 to 3.804) 3.466 (2.807 to 4.276)
Canakinumab/placebo 0.847 (0.665 to 1.080) 0.784 (0.611 to 1.008)
Adiponectin, ng/ml
Log-transformed results
Canakinumab n ¼ 36; 8.265 (8.208 to 8.323)
Placebo n ¼ 36; 8.284 (8.227 to 8.342)
Canakinumab vs. placebo –0.019 (–0.084 to 0.046), p ¼ 0.57
Back-transformed results
Canakinumab 3,885 (3,670 to 4,117)
Placebo 3,960 (3,741 to 4,196)
Canakinumab/placebo 0.981 (0.919 to 1.047)
*Change from baseline, not log-transformed. LSMs of outcomes (95% CIs) with number of patients reported from the analysis of covariance of the log-transformed outcome at
3 and 12 months, adjusted for log-transformed baseline of outcome and including the 2-level factor type 2 diabetes mellitus or impaired glucose tolerance as a covariate.
Inclusion of patients is according to the protocol. The treatment effect is reported as the difference between the canakinumab arm and the placebo arm and after
back-transforming the treatment effect as the ratio of the levels in the canakinumab arm to the placebo arm. The LSMs are back-transformed (geometric means).
Abbreviations as in Tables 1 and 3.
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TABLE 5 MACE
MACE Placebo Canakinumab p Value
Group
All
N 94 95
Yes 7 (7) 10 (11) 0.612
No 87 (93) 85 (89)
Type 2 diabetes mellitus
N 81 81
Yes 6 (7) 9 (11) 0.589
No 75 (93) 72 (89)
Impaired glucose tolerance
N 13 14
Yes 1 (8) 1 (7) 1.000
No 12 (92) 13 (93)
Values are n (%) unless otherwise indicated.
MACE ¼ major adverse cardiac events.
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1778Vascular 18ﬂudeoxyglucose positron emission to-
mography has been used effectively to evaluate ca-
rotid and aortic plaque macrophage activity in clinical
trials, and this test may have been an alternative
imaging modality (23,28,29). However, changes in
macrophage function are associated with changes in
substrate utilization and mode of energy generation
(30). Therefore, using 18ﬂudeoxyglucose positron
emission tomography to identify macrophages on the
basis of their glycolytic activity may provide onlyTRAL ILLUSTRATION Effects of IL-1b Inhibition
H
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kin (IL)-1b seems important in the pathogenesis of atherosclerosis. In this pl
s and either type 2 diabetes mellitus or impaired glucose tolerance, the IL-1b
ntly affect measures of vascular structure or function. LDL ¼ low-density lippartial insight into the relevant biology with respect
to IL-1b inhibition, and could even be misleading (31).
This study focused on changes in vessel wall
structure and function. In doing so, we intended to
obtain insights into the possible effects of canakinu-
mab on different manifestations, or stages, of vessel
wall pathology. Despite this expansive approach, we
observed no signiﬁcant effects on the vessel wall.
Given the discordance with animal studies, one
should also consider the possibility that previously
observed beneﬁcial effects of IL-1b inhibition need
not have been realized directly at the arterial level.
Accumulating evidence suggests roles for peripheral
monocytes in accelerating atherosclerosis in response
to inﬂammatory stimuli (32). Indeed, IL-1b enhances
hematopoietic stem cell proliferation and leukocyte
production after acute myocardial infarction in mice
and is reduced by administration of anti–IL-1b anti-
bodies (33).
In mice, most studies of IL-1b inhibition have
shown reduced atherosclerosis and/or plaque
inﬂammation; however, 1 study found that inactiva-
tion of IL-1 signaling through loss of the IL-1 receptor
type 1 in apolipoprotein E–/– mice promoted mul-
tiple indexes of atherosclerotic plaque instability,
including reduced plaque smooth muscle cell con-
tent, reduced plaque collagen content, and impaired
outward vessel remodeling, leading to reduced lumen
size (34). Our study in humans found no evidence ofigh-sensitivity
-reactive protein
Effect on
Inflammation
Effect on
lipids
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nterleukin-6 (IL-6)
Triglycerides
Lipoprotein (a)
n patients with evidence of atherosclerosis
red glucose intolerance?
acebo-controlled trial in patients with evidence of clinical athero-
inhibitor canakinumab reduced measures of inﬂammation but did not
oprotein.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Markers of
inﬂammation such as C-reactive protein and serum amyloid A are
related to cardiovascular prognosis in patients with atheroscle-
rosis. Canakinumab, a monoclonal antibody that inhibits IL-1b,
reduces these markers without measurable effects on arterial
structure or function.
TRANSLATIONAL OUTLOOK: The therapeutic efﬁcacy of
canakinumab in patients with vascular disease and T2DM or
glucose intolerance will be assessed in a multicenter clinical trial.
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1779changes in aortic characteristics according to distensi-
bility measures at multiple sites. In theory, it would be
possible for changes in lumen area/outward remodel-
ing to be present despite no change in wall area,
because wall area is derived by subtracting the lumen
area from the total vessel area. Examining these mea-
sures individually provides information on tendencies
for luminal constriction or outward remodeling. In
human atherosclerosis, we found no change in lumen
area or adverse effect on outward vessel remodeling.
Canakinumab had no effect on fasting glucose,
HbA1c, or measures of insulin sensitivity in the present
study. This outcome does not agree with the ﬁndings
of Larsen et al. (16), who used the IL-1RA anakinra. The
apparent discrepancy may reﬂect better glycemic
control at baseline in our study, in which >50% of
patients had HbA1c levels <7% compared with a mean
HbA1c level >8.5% in the treatment arm of the ana-
kinra trial. However, canakinumab administration did
result in an increase in plasma triglyceride levels, as
reported previously for this agent (20). The underlying
mechanism is not clear. Other treatments targeting
inﬂammation have also been associated with elevated
levels of very-low-density lipoprotein triglycerides
(35). There was also a marginal but statistically sig-
niﬁcant elevation in total cholesterol levels, with an
increase by 18.5 mg/dl after 3 months’ treatment.
Conversely, lipoprotein(a) was signiﬁcantly reduced
by canakinumab at both time points.
STUDY LIMITATIONS. This study did not evaluate
atherosclerosis at the carotid bifurcation, where the
burden of disease is often greatest, nor did it quantify
plaque lipid content. Although MRI scans provide
highly reproducible measures of plaque structure and
vessel function, they offer no direct measure of plaque
inﬂammation. It is possible for drugs tomarkedly affect
plaque biology without altering plaque size, particu-
larly on short-term follow-up (36). In this study, no
attempt was made to select subjects on the basis of in-
ﬂammatory status. More reﬁned patient selection may
enhance the effectiveness of drugs that are directed
toward speciﬁc processes and pathways. Finally, we
cannot exclude the possibility that the dose of canaki-
numab was not high enough to generate a maximal
effect on atherosclerotic burden, although the dose
was sufﬁcient to lower both hs-CRP and IL-6 levels.
There were no signiﬁcant differences in adverse
events between the 2 groups, nor were any unex-
pected adverse outcomes identiﬁed. However, this
small study cannot thoroughly or systematically
evaluate the safety of canakinumab. The question of
clinical efﬁcacy clearly remains open. This question
will be answered by the Phase III trial, CANTOS,which randomized >10,000 patients with hs-CRP $2
mg/l to treatment in a secondary prevention popula-
tion; the goal is to evaluate the composite primary
endpoint of nonfatal myocardial infarction, nonfatal
stroke, or cardiovascular death (20,21).
CONCLUSIONS
In patients with T2DM and established cardiovascular
disease, canakinumab reduced markers of inﬂamma-
tion (hs-CRP and IL-6) compared with placebo. Treat-
ment with canakinumab also increased levels of
triglycerides and total cholesterol but reduced
lipoprotein(a) levels. Despite measurable effects on
systemic markers of inﬂammation, there was no
statistically signiﬁcant effect on measures of vascular
structure or function. Effects of canakinumab on pla-
que inﬂammation or on leukocyte function elsewhere
may be undetectable with current imaging technolo-
gies. The results of this Phase II trial leave open the
important question of clinical efﬁcacy, which will be
addressed by the multinational Phase III trial CANTOS.
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